Selling, general and administrative expenses were relatively constant at $7.4 million for the fourth quarter of 2012, compared to $6.9 million for the same period in 2011. Selling, general and administrative expenses were $30.2 million for 2012, compared to $30.4 million for 2011.
As a result of the termination and transition agreement with GSK that resolved all pending litigation between the parties, XenoPort recorded a non-cash gain on litigation settlement of $20.5 million in the fourth quarter of 2012, which resulted in a profitable quarter.
Net income for the fourth quarter of 2012 was $3.0 million, compared to a net loss of $16.9 million for the same period in 2011. Net income per basic and diluted share was $0.07 for the fourth quarter of 2012, compared to a net loss per basic and diluted share of $0.48 for the same period in 2011. Net loss for 2012 was $30.8 million, compared to a net loss of $33.4 million in 2011. Net loss per basic and diluted share was $0.78 for 2012, compared to a net loss per basic and diluted share of $0.94 for 2011.
XenoPort announced that it expects the net use of cash for 2013 to be in the range of $100 million to $110 million (net use of cash is the difference between the anticipated balances of cash and cash equivalents plus short-term investments at 12/31/13 and the actual balances at 12/31/12).
XenoPort will host a conference call at 5:00 p.m. Eastern Time today to discuss its financial results and provide an update on XenoPort’s business. To access the conference call via the Internet, go to
. To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 19426152.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at
, or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 19426152.
XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.
is our first approved product in the United States. GSK holds commercialization rights for
in the United States during a transition period ending on April 30, 2013, following which XenoPort will be responsible for the further development, manufacturing and commercialization of
is approved and is being marketed in Japan. Astellas Pharma Inc. holds all development and commercialization rights for
in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease and RRMS.
To learn more about XenoPort, please visit the company Website at
This press release contains “forward-looking” statements, including, without limitation, all statements related to GSK’s future activities during the transition period with respect to
; XenoPort’s future development, manufacturing and commercialization activities with respect to
following such transition period; growing the
business in a cost-efficient manner and potentially expanding XenoPort’s commercial efforts; the release of AP clinical data and the timing and results thereof; the potential submission of an NDA for AP for the treatment of spasticity and the timing thereof; XenoPort’s future clinical development programs for XP23829, including potential indications for development; the therapeutic and commercial potential of XenoPort’s product candidates; the suitability of AP as a treatment of spasticity; the suitability of XP23829 as a treatment for RRMS, psoriasis or other potential indications; and
XenoPort’s expected net cash usage for 2013
. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “assume,” “expects,” “hope,” “intends,” “potential,” “will,” “would” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to XenoPort’s lack of commercialization experience and its ability to establish, or contract with third parties to establish, sales, marketing, distribution, supply chain and other sufficient capabilities to assume responsibility for and to market and sell
following the transition period with respect to
; XenoPort’s ability to successfully market and sell
following the transition period, including its ability to obtain appropriate pricing and reimbursement for
in an increasingly challenging environment, and whether any such sales will be sufficient to outweigh the costs of establishing and maintaining sales, marketing, distribution, supply chain and other capabilities;
XenoPort’s ability to comply with applicable regulatory guidelines and requirements with respect to the marketing and manufacturing of
post-marketing commitments or requirements mandated by the FDA;
XenoPort’s need for additional funding and the risk that XenoPort could utilize its available capital resources sooner than it expects; the uncertainty of the FDA approval process and other regulatory requirements; the uncertain results and timing of clinical trials; XenoPort’s ability to successfully conduct clinical trials in the anticipated timeframes, or at all; the uncertain therapeutic and commercial value of XenoPort’s product candidates; and risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results. These and other risk factors are discussed under the heading “Risk Factors” in XenoPort’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed with the Securities and Exchange Commission on October 25, 2012, and in future filings and reports by XenoPort, including its Annual Report on Form 10-K for the year ended December 31, 2012. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.